lipid-lowering efficacy - Globe Thesis

Keyword [lipid-lowering efficacy] Result: 1 - 19 \| Page: 1 of 1
1.	Yiqihuoxue Spleen Law Lipid Lowering Efficacy Observed With The Apoe Gene Polymorphisms In Clinical Research
2.	Association Study Of CYP3A418B, CYP3A53 And MDR1C3435T Genetic Polymorphism With Lipid-lowering Efficacy Of Atorvastatin
3.	Effect Of SLC21A6 Gene Polymorphism On Lipid-lowering Efficacy Of Simvastatin And Atorvastatin
4.	Effect Of CYP3A4, CYP3A5 And MDR1 Genetic Polymorphisms On Lipid-lowering Efficacy Of Simvastatin In Chinese Hyperlipidemic Patients
5.	Clinical Research Of Inflammatory Cytokines On Lipid-lowering Efficacy Of Statins
6.	Effect Of Cyp3ap1 And Abcc2 Gene Polymorphism On Lipid-lowering Efficacy Of Atorvastatin
7.	Contained The Study Of The Relationship Of Lipid Levels And Lipid-lowering Efficacy Of The Apolipoprotein E Gene Polymorphism And Hyperlipidemia Phlegm And Blood Stasis
8.	Clinical Study Of Combination Lipid Lowering Therapy On The Lipid Lowering Efficacy And Rognosis Of The Patients With Acute Coronary Syndrome
9.	Atorvastatin Joint According To Fold The Mab Lipid-lowering Efficacy Observed In Patients With Coronary Heart Disease(CHD)
10.	The Comparison Of Rosuvastatin And Rtorvastatin On The Safety And Efficacy In Intensive Lipid-lowering For Patients With Acute Cerebral Infarction
11.	To Study The Association Between The SNP Rs1065852 In The CYP2D6 Gene And The Lipid-lowering Efficacy Of Atorvastatin On The Treatment Of Acute Cerebral Infarction(ACI)
12.	The Effects Of Lipid Metabolism Related Gene Polyporphisms And DNA Methylation On The Baseline Lipid Levels And Lipid-lowering Efficacy Of Simvastatin
13.	The Study Of The Efficacy And Safety Of Different Doses Of Atorvastatin In The Treatment Of Atherosclerotic Cerebral Infarction In The Aged
14.	The Gene Polymorphism Of SLCOIBI And Its Correlation With Resuvastatin Lipid-lowering Efficacy And Safety In Kunming Han Population
15.	The Lipid-lowering Efficacy And Anti-inflammatory Effects Of PCSK9 Inhibitors In Patients With Dyslipidemia In Type 2 Diabetes
16.	The Short-term Lipid-lowering Efficacy And Safety Analysis Of PCSK9 Inhibitor Evolocumab In Extremely High-risk Patients With Acute Coronary Syndrome
17.	Meta-Analysis Of The Lipid-Lowering Efficacy And Cardiovascular Safety Of PCSK9 Inhibitors With ACS
18.	Evaluation Of Lipid-lowering Efficacy And Molecular Mechanism Of Sargassum Fusiforme Fucoidan
19.	The Clinical Efficacy Of PCSK9 Inhibitor(Alirocumab) In The Treatment Of Hyperlipidemia With Carotid Plaque
<<First <Prev Next> Last>> Jump to